Resource Summary Report

Generated by NIF on Sep 21, 2026

SW626

RRID:CVCL_1725
Type: Cell Line

Proper Citation

RRID:CVCL_1725

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1725

Proper Citation: RRID:CVCL_1725

Description: Cell line SW626 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Colon adenocarcinoma

Defining Citation: PMID:327080, PMID:833871, PMID:3518877, PMID:6220172, PMID:6582512, PMID:9698466, PMID:10433623, PMID:11314036, PMID:12068308, PMID:20106510, PMID:20164919, PMID:23415752, PMID:25846456, PMID:25877200, PMID:27397505, PMID:28196595, PMID:30894373, PMID:30971826, PMID:35839778

Comments: Population: Caucasian., From: Scott and White Clinic; Temple; USA., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Misclassified. Although established from a surgical specimen from a cystadenocarcinoma of the ovary in a 46 year old female Caucasian, it now seems likely that it was established from an ovarian metastasis of a colonic carcinoma (PubMed=10433623)..

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SW626

Synonyms: SW-626, SW 626

Cross References: BTO:BTO_0001881, CLO:CLO_0009197, CLO:CLO_0009222, CLDB:cl4446, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-3610, ATCC:HTB-78,

BioGRID_ORCS_Cell_line:1030, BioSample:SAMN03472756, BioSample:SAMN03472876, cancercelllines:CVCL_1725, CCRID:4201HUM-CCTCC00112, CCTCC:GDC0112, Cell_Model_Passport:SIDM01168, ChEMBL-Cells:CHEMBL3308130, ChEMBL-Targets:CHEMBL1075593, CLS:305093, Cosmic:724882, Cosmic:844346, Cosmic:849608, Cosmic:867865, Cosmic:897437, Cosmic:909753, Cosmic:920358, Cosmic:948285, Cosmic:949229, Cosmic:1044244, Cosmic:1093559, Cosmic:1113284, Cosmic:1312194, Cosmic:1707572, Cosmic:2582804, Cosmic:2674699, Cosmic-CLP:909753, DepMap:ACH-001399, ECACC:91091203, EGA:EGAS00001000978, GDSC:909753, GEO:GSM186459, GEO:GSM186460, GEO:GSM313714, GEO:GSM659406, GEO:GSM784571, GEO:GSM1670509, IARC_TP53:27252, KCB:KCB 2013039YJ, LINCS_LDP:LCL-1529, PharmacoDB:SW626_1542_2019, PRIDE:PXD030304, Progenetix:CVCL_1725, PubChem_Cell_line:CVCL_1725, Wikidata:Q54971190

ID: CVCL_1725

Record Creation Time: 20220427T221615+0000

Record Last Update: 20260920T005911+0000

Ratings and Alerts

No rating or validation information has been found for SW626.

Warning: Problematic cell line: Misclassified. Although established from a surgical specimen from a cystadenocarcinoma of the ovary in a 46 year old female Caucasian, it now seems likely that it was established from an ovarian metastasis of a colonic carcinoma (PubMed=10433623).
Population: Caucasian., From: Scott and White Clinic; Temple; USA., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Misclassified. Although established from a surgical specimen from a cystadenocarcinoma of the ovary in a 46 year old female Caucasian, it now seems likely that it was established from an ovarian metastasis of a colonic carcinoma (PubMed=10433623)..

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Xu X, et al. (2024) FOXF1 promotes ovarian cancer metastasis by facilitating HMGA2-mediated USP30-dependent S100A6 deubiquitination. Biochimica et biophysica acta. Molecular basis of disease, 1871(3), 167633.

González-Cantó E, et al. (2024) Reduced Levels of miR-145-3p Drive Cell Cycle Progression in Advanced High-Grade Serous Ovarian Cancer. Cells, 13(22).

Pacini C, et al. (2024) A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization. Cancer cell, 42(2), 301.

Jin L, et al. (2018) MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. Cancer cell, 34(2), 315.